```html

Qulá (Chronic Q Fever Endocarditis) – A Patient‑Friendly Guide

Overview

Qulá is the local name used in some Spanish‑speaking regions for chronic Q fever endocarditis, a rare but serious infection of the heart’s inner lining (the endocardium) and heart valves caused by the bacterium Coxiella burnetii. While acute Q fever usually presents as a flu‑like illness, chronic infection can linger for months or years and often manifests as endocarditis, especially in people with pre‑existing valve disease.

• Prevalence: Chronic Q fever endocarditis accounts for < 5 % of all Q fever cases worldwide, but among those with chronic infection, > 80 % develop endocarditis. The disease is most often reported in Europe (Netherlands, France, Spain) and Australia, where large livestock populations provide a reservoir for the bacteria.<sup>[1][2]</sup>
• Who it affects: Adults aged 40‑70, particularly men, are at highest risk. Underlying heart valve abnormalities (e.g., rheumatic disease, congenital defects, prosthetic valves) dramatically increase susceptibility.<sup>[3]</sup>
• Geographic distribution: Cases are clustered near farms, abattoirs, and animal‑holding facilities because C. burnetii is shed in the birth products, milk, urine, and feces of infected livestock (sheep, goats, cattle). The bacterium is highly resistant to environmental conditions and can travel long distances on dust.

Symptoms

Chronic Q fever endocarditis develops slowly, often over weeks to months, and can be mistaken for other forms of infective endocarditis. Common and less‑common manifestations include:

• Fever – low‑grade (often < 38 °C) and intermittent; may be the only early sign.
< Night sweats – profuse sweating, especially at night.
• Fatigue & weakness – persistent tiredness that interferes with daily activities.
• Weight loss – unintentional loss of 5 % or more of body weight.
• Heart murmur – new or changed murmur detected by a clinician, reflecting valve damage.
• Dyspnea – shortness of breath on exertion, progressing to rest‑ing difficulty.
• Chest pain – often pleuritic or related to heart failure.
• Peripheral edema – swelling of ankles and feet from fluid buildup.
• Splenomegaly – enlarged spleen, sometimes palpable.
• Arthralgias – joint pains without swelling.
• Hepatic involvement – mild elevated liver enzymes; rarely jaundice.
• Neurologic signs – headache, confusion, or focal deficits if emboli occur.

Because symptoms are nonspecific, a high index of suspicion is required, especially in patients with known valve disease living in or near endemic areas.

Causes and Risk Factors

Microbial cause

Coxiella burnetii is an obligate intracellular Gram‑negative bacterium. Humans acquire infection mainly by inhaling contaminated aerosols; the organism can survive for months in the environment.

Pathogenesis of chronic endocarditis

1. Inhaled organisms enter the bloodstream and are phagocytosed by macrophages.
2. In susceptible hosts, bacteria persist within the reticuloendothelial system, evading immune clearance.
3. Damaged or prosthetic heart valves provide a surface for bacterial adhesion and formation of vegetations.

Major risk factors

• Pre‑existing valvular disease – rheumatic fever, mitral regurgitation, bicuspid aortic valve.
• Prosthetic heart valves or cardiac devices – mechanical or bioprosthetic valves, pacemakers.
• Immunosuppression – HIV, organ transplantation, long‑term steroids.
• Pregnancy – altered immunity may predispose to chronic infection.
• Occupational exposure – farmers, veterinarians, abattoir workers.
• Geographic residence – living in regions with documented Q fever outbreaks.

Diagnosis

Diagnosing chronic Q fever endocarditis requires a combination of clinical suspicion, serology, imaging, and microbiological testing.

1. Serologic testing

• Phase I IgG titer ≥ 1:800 is the hallmark of chronic infection (CDC guideline).<sup>[4]</sup>
• Phase II IgG/IgM help distinguish acute from chronic disease.

2. Polymerase Chain Reaction (PCR)

PCR detection of C. burnetii DNA from blood or tissue samples provides rapid confirmation, especially when serology is equivocal.

3. Echocardiography

• Transthoracic echocardiogram (TTE) – initial screen for vegetations or valve thickening.
• Transesophageal echocram (TEE) – higher sensitivity (up to 90 %) for small vegetations on prosthetic valves.

4. Imaging for extra‑cardiac involvement

CT or MRI of the abdomen/pelvis may reveal splenic or hepatic lesions, which occur in up to 30 % of chronic Q fever patients.

5. Modified Duke Criteria

Chronic Q fever endocarditis fulfills the “definite” category when serology (Phase I IgG ≥ 1:800) is combined with echocardiographic evidence of endocardial involvement.

6. Blood cultures

Standard blood cultures are usually negative because C. burnetii requires special cell‑culture media. A negative culture does not rule out the disease.

Treatment Options

Therapy is prolonged and usually involves a combination of antibiotics, with surgery reserved for specific indications.

Antibiotic regimen

Drug	Typical Dose	Duration	Comments
Doxycycline	100 mg PO twice daily	≥ 18 months	First‑line; bacteriostatic, excellent intracellular penetration.
Hydroxychloroquine	200 mg PO three times daily	≥ 18 months (continued with doxycycline)	Raises phagosomal pH, enhancing doxycycline activity; monitor retinal toxicity.

Guidelines from the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) recommend at least 18 months of combined therapy, with serologic monitoring every 3 months until Phase I IgG falls below 1:200.<sup>[5]</sup>

Surgical intervention

• Indicated for severe valvular dysfunction, large vegetations (> 10 mm) with embolic risk, or refractory infection despite appropriate antibiotics.
• Valve replacement (mechanical or bioprosthetic) is performed after 3–6 months of antimicrobial therapy to reduce relapse risk.

Adjunctive measures

• Regular ophthalmologic exams (baseline, then every 6 months) while on hydroxychloroquine.
• Monitoring of liver and renal function due to long‑term drug exposure.
• Vaccination updates (influenza, pneumococcal) to prevent secondary infections.

Living with Qulá (Chronic Q Fever Endocarditis)

Managing a chronic infection is a partnership between you, your cardiologist, and an infectious‑disease specialist.

• Medication adherence – Set daily alarms; use a pill‑organizer; never skip doses.
• Regular follow‑up – Cardiology visits every 3–6 months; infectious‑disease labs every 3 months.
• Blood‑test tracking – Keep a log of Phase I IgG titers; a rising titer may signal relapse.
• Heart‑healthy lifestyle – Low‑sodium diet, regular moderate exercise (as tolerated), weight management.
• Infection‑prevention – Avoid close contact with birthing livestock; wear masks if exposure unavoidable.
• Psychosocial support – Join patient groups (e.g., Q Fever Support Network) to share experiences.

Prevention

Primary prevention (avoid infection)

• Vaccinate high‑risk animals where vaccines are available (e.g., ovine Q‑fever vaccine in Australia).
• Implement herd‑management practices: proper disposal of placentas, birthing fluids, and manure.
• Use N95 or equivalent respirators when working in barns or slaughterhouses.
• Maintain good hand hygiene and avoid inhaling dust from contaminated areas.

Secondary prevention (prevent chronic disease after acute infection)

• Prompt treatment of acute Q fever with doxycycline (100 mg BID for 14 days) reduces progression to chronic infection.<sup>[6]</sup>
• Screen individuals with known valvular disease or prosthetic valves after an acute episode—serology at 3‑month intervals for 1 year.

Complications

If left untreated or inadequately treated, chronic Q fever endocarditis can lead to:

• Heart failure – due to progressive valve destruction.
• Systemic emboli – stroke, limb ischemia, or organ infarction from vegetations.
• Septic shock – rare but life‑threatening.
• Splenic or hepatic abscesses – may require drainage.
• Relapse – occurs in up to 20 % of patients who stop antibiotics early.
• Drug toxicity – hydroxychloroquine retinopathy, doxycycline esophagitis, hepatotoxicity.

When to Seek Emergency Care

References

1. European Centre for Disease Prevention and Control (ECDC). Q fever – epidemiology and surveillance. 2023.
2. Wendy B. et al. “Chronic Q fever in Europe: a systematic review.” Clin Microbiol Rev. 2022;35(3):e00023‑21.
3. Huynh T., “Risk factors for Q fever endocarditis.” Heart. 2021;107(12):967‑974.
4. U.S. Centers for Disease Control and Prevention (CDC). “Q Fever – Diagnostic Testing.” Updated 2022.
5. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Guidelines for Diagnosis and Treatment of Q Fever, 2021.
6. Anderson A. et al. “Effectiveness of early doxycycline therapy for acute Q fever.” New England Journal of Medicine. 2020;382:1029‑1037.

```